Laman UtamaBHM0 • FRA
add
BACHEM HOLDING AG
Tutup sebelumnya
€73.10
Julat hari
€72.40 - €72.40
Julat tahun
€51.25 - €81.50
Permodalan pasaran
5.09B CHF
Bilangan Purata
27.00
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
SWX
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (CHF) | Dis 2025info | Perubahan T/T |
|---|---|---|
Hasil | 191.04J | 4.70% |
Perbelanjaan pengendalian | 4.65J | -61.22% |
Pendapatan bersih | 49.35J | 17.36% |
Margin untung bersih | 25.83 | 12.11% |
Pendapatan bagi setiap syer | — | — |
EBITDA | 63.83J | 9.45% |
Kadar cukai berkesan | 1.53% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (CHF) | Dis 2025info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 30.99J | -67.45% |
Jumlah aset | 2.11B | 9.66% |
Jumlah liabiliti | 650.41J | 22.28% |
Jumlah ekuiti | 1.46B | — |
Syer tertunggak | 74.94J | — |
Harga kepada buku | 3.76 | — |
Pulangan pada aset | 5.95% | — |
Pulangan pada modal | 8.26% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (CHF) | Dis 2025info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | 49.35J | 17.36% |
Tunai daripada operasi | 92.80J | 220.31% |
Tunai daripada pelaburan | -89.05J | -624.68% |
Tunai daripada pembiayaan | -2.81J | -391.01% |
Perubahan bersih dalam tunai | 923.00K | -94.31% |
Aliran tunai bebas | -43.10J | -92.30% |
Perihal
Bachem Holding AG is a Swiss biotechnology company specializing in the development and manufacture of peptides and complex organic molecules for use as active pharmaceutical ingredients. The company focuses on peptide-based therapeutics, including large-scale commercial production and process development for pharmaceutical applications. It was founded in 1971 and is a subsidiary of Ingro Finanz AG.
The head office is in Bubendorf in the canton of Basel-Landschaft. Bachem operates production facilities in Vionnaz, Vista and Torrance, and St Helens, as well as a sales and distribution site in Tokyo.
Bachem is one of the largest manufacturers of peptide-based APIs globally, supplying pharmaceutical and biotechnology companies with products used in both clinical development and commercial therapies.
In recent years, the company has expanded its manufacturing capacity, including new large-scale production facilities in Switzerland and the United States.
At the end of 2025, the company employed 2,511 people, reported revenue of CHF 695.1 million, and net income of CHF 148.8 million. Wikipedia
CEO
Diasaskan
1971
Tapak web
Pekerja
2,363